| Schedule of Revenue from Collaborators |
Net revenues from collaborations consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (In thousands) | 2026 | | 2025 | | 2026 | | 2025 | Roche | $ | 39,107 | | | $ | 326,604 | | | $ | 116,636 | | | $ | 361,927 | | | Regeneron Pharmaceuticals | 32,334 | | | 22,542 | | | 83,690 | | | 106,123 | | | | | | | | | | | | | | | | | | | Other | 35 | | | 2,596 | | | 390 | | | 44,373 | | Total net revenues from collaborations | $ | 71,476 | | | $ | 351,742 | | | $ | 200,716 | | | $ | 512,423 | |
Net revenues from collaborations recognized under the Roche Agreement consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (In thousands) | | | 2026 | | 2025 | | 2026 | | 2025 | Roche License Obligation | | | $ | — | | | $ | 300,000 | | | $ | — | | | $ | 300,000 | | Roche Development Services Obligation | | | $ | 37,557 | | | $ | 25,166 | | | 112,196 | | | 57,696 | | | | | | | | | | | | Other | | | 1,550 | | | 1,438 | | | 4,440 | | | 4,231 | | Total | | | $ | 39,107 | | | $ | 326,604 | | | $ | 116,636 | | | $ | 361,927 | |
Net revenues from collaborations recognized under the Regeneron Collaboration consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (In thousands) | 2026 | | 2025 | | 2026 | | 2025 | Research Services Obligation | $ | 7,345 | | | $ | 12,540 | | | $ | 13,176 | | | $ | 39,306 | | C5 License Obligation | — | | | — | | | — | | | 21,370 | | | | | | | | | | | | | | | | | | Regeneron Technology Transfer Obligation | — | | | — | | | — | | | 2,431 | | Other license programs | 24,989 | | | 10,002 | | | 70,514 | | | 43,016 | | Total | $ | 32,334 | | | $ | 22,542 | | | $ | 83,690 | | | $ | 106,123 | |
|
| Schedule of Deferred Revenue |
The following table presents the balance of our receivables and contract liabilities related to our collaboration agreements: | | | | | | | | | | | | | (In thousands) | As of September 30, 2026 | | As of December 31, 2025 | Receivables included in accounts receivable, net | $ | 89,603 | | | $ | 48,823 | | | | | | | Contract liabilities included in deferred revenue | $ | 11,669 | | | $ | 4,845 | |
|
| Schedule of Allocated Transaction Price Based on Accounting Guidance |
The following table provides a summary of the transaction price allocated to each performance obligation: | | | | | | | | | | | (In thousands) | | As of September 30, 2026 | | | Roche License Obligation | | $ | 675,000 | | | | Roche Development Services Obligation | | 1,061,167 | | | | Roche Technology Transfer Obligation | | 2,000 | | | | | | $ | 1,738,167 | | | |
|